Cargando…

A Selective Reduction of Osteosarcoma by Mitochondrial Apoptosis Using Hydroxyapatite Nanoparticles

BACKGROUND: In recent years, using hydroxyapatite nanoparticles (HANPs) for tumor therapy attracted increasing attention because HANPs were found to selectively suppress the growth of tumor cells but exhibit ignorable toxicity to normal cells. PURPOSE: This study aimed to investigate the capacities...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Hongfeng, Liu, Shuo, Chen, Siyu, Hua, Yuchen, Li, Xiangfeng, Zeng, Qin, Zhou, Yong, Yang, Xiao, Zhu, Xiangdong, Tu, Chongqi, Zhang, Xingdong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9423115/
https://www.ncbi.nlm.nih.gov/pubmed/36046839
http://dx.doi.org/10.2147/IJN.S375950
_version_ 1784777950538760192
author Wu, Hongfeng
Liu, Shuo
Chen, Siyu
Hua, Yuchen
Li, Xiangfeng
Zeng, Qin
Zhou, Yong
Yang, Xiao
Zhu, Xiangdong
Tu, Chongqi
Zhang, Xingdong
author_facet Wu, Hongfeng
Liu, Shuo
Chen, Siyu
Hua, Yuchen
Li, Xiangfeng
Zeng, Qin
Zhou, Yong
Yang, Xiao
Zhu, Xiangdong
Tu, Chongqi
Zhang, Xingdong
author_sort Wu, Hongfeng
collection PubMed
description BACKGROUND: In recent years, using hydroxyapatite nanoparticles (HANPs) for tumor therapy attracted increasing attention because HANPs were found to selectively suppress the growth of tumor cells but exhibit ignorable toxicity to normal cells. PURPOSE: This study aimed to investigate the capacities of HANPs with different morphologies and particle sizes against two kinds of osteosarcoma (OS) cells, human OS 143B cells and rat OS UMR106 cells. METHODS: Six kinds of HANPs with different morphologies and particle sizes were prepared by wet chemical method. Then, the antitumor effect of these nanoparticles was characterized by means of in vitro cell experiments and in vivo tumor-bearing mice model. The underlying antitumor mechanism involving mitochondrial apoptosis was also investigated by analysis of intracellular calcium, expression of apoptosis-related genes, reactive oxygen species (ROS), and the endocytosis efficiency of the particles in tumor cells. RESULTS: Both in vitro cell experiments and in vivo mice model evaluation revealed the anti-OS performance of HANPs depended on the concentration, morphology, and particle size of the nanoparticles, as well as the OS cell lines. Among the six HANPs, rod-like HANPs (R-HANPs) showed the best inhibitory activity on 143B cells, while needle-like HANPs (N-HANPs) inhibited the growth of UMR106 cells most efficiently. We further demonstrated that HANPs induced mitochondrial apoptosis by selectively raising intracellular Ca(2+) and the gene expression levels of mitochondrial apoptosis-related molecules, and depolarizing mitochondrial membrane potential in tumor cells but not in MC3T3-E1, a mouse pre-osteoblast line. Additionally, the anti-OS activity of HANPs also linked with the endocytosis efficiency of the particles in the tumor cells, and their ability to drive oxidative damage and immunogenic cell death (ICD). CONCLUSION: The current study provides an effective strategy for OS therapy where the effectiveness was associated with the particle morphology and cell line.
format Online
Article
Text
id pubmed-9423115
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-94231152022-08-30 A Selective Reduction of Osteosarcoma by Mitochondrial Apoptosis Using Hydroxyapatite Nanoparticles Wu, Hongfeng Liu, Shuo Chen, Siyu Hua, Yuchen Li, Xiangfeng Zeng, Qin Zhou, Yong Yang, Xiao Zhu, Xiangdong Tu, Chongqi Zhang, Xingdong Int J Nanomedicine Original Research BACKGROUND: In recent years, using hydroxyapatite nanoparticles (HANPs) for tumor therapy attracted increasing attention because HANPs were found to selectively suppress the growth of tumor cells but exhibit ignorable toxicity to normal cells. PURPOSE: This study aimed to investigate the capacities of HANPs with different morphologies and particle sizes against two kinds of osteosarcoma (OS) cells, human OS 143B cells and rat OS UMR106 cells. METHODS: Six kinds of HANPs with different morphologies and particle sizes were prepared by wet chemical method. Then, the antitumor effect of these nanoparticles was characterized by means of in vitro cell experiments and in vivo tumor-bearing mice model. The underlying antitumor mechanism involving mitochondrial apoptosis was also investigated by analysis of intracellular calcium, expression of apoptosis-related genes, reactive oxygen species (ROS), and the endocytosis efficiency of the particles in tumor cells. RESULTS: Both in vitro cell experiments and in vivo mice model evaluation revealed the anti-OS performance of HANPs depended on the concentration, morphology, and particle size of the nanoparticles, as well as the OS cell lines. Among the six HANPs, rod-like HANPs (R-HANPs) showed the best inhibitory activity on 143B cells, while needle-like HANPs (N-HANPs) inhibited the growth of UMR106 cells most efficiently. We further demonstrated that HANPs induced mitochondrial apoptosis by selectively raising intracellular Ca(2+) and the gene expression levels of mitochondrial apoptosis-related molecules, and depolarizing mitochondrial membrane potential in tumor cells but not in MC3T3-E1, a mouse pre-osteoblast line. Additionally, the anti-OS activity of HANPs also linked with the endocytosis efficiency of the particles in the tumor cells, and their ability to drive oxidative damage and immunogenic cell death (ICD). CONCLUSION: The current study provides an effective strategy for OS therapy where the effectiveness was associated with the particle morphology and cell line. Dove 2022-08-25 /pmc/articles/PMC9423115/ /pubmed/36046839 http://dx.doi.org/10.2147/IJN.S375950 Text en © 2022 Wu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Wu, Hongfeng
Liu, Shuo
Chen, Siyu
Hua, Yuchen
Li, Xiangfeng
Zeng, Qin
Zhou, Yong
Yang, Xiao
Zhu, Xiangdong
Tu, Chongqi
Zhang, Xingdong
A Selective Reduction of Osteosarcoma by Mitochondrial Apoptosis Using Hydroxyapatite Nanoparticles
title A Selective Reduction of Osteosarcoma by Mitochondrial Apoptosis Using Hydroxyapatite Nanoparticles
title_full A Selective Reduction of Osteosarcoma by Mitochondrial Apoptosis Using Hydroxyapatite Nanoparticles
title_fullStr A Selective Reduction of Osteosarcoma by Mitochondrial Apoptosis Using Hydroxyapatite Nanoparticles
title_full_unstemmed A Selective Reduction of Osteosarcoma by Mitochondrial Apoptosis Using Hydroxyapatite Nanoparticles
title_short A Selective Reduction of Osteosarcoma by Mitochondrial Apoptosis Using Hydroxyapatite Nanoparticles
title_sort selective reduction of osteosarcoma by mitochondrial apoptosis using hydroxyapatite nanoparticles
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9423115/
https://www.ncbi.nlm.nih.gov/pubmed/36046839
http://dx.doi.org/10.2147/IJN.S375950
work_keys_str_mv AT wuhongfeng aselectivereductionofosteosarcomabymitochondrialapoptosisusinghydroxyapatitenanoparticles
AT liushuo aselectivereductionofosteosarcomabymitochondrialapoptosisusinghydroxyapatitenanoparticles
AT chensiyu aselectivereductionofosteosarcomabymitochondrialapoptosisusinghydroxyapatitenanoparticles
AT huayuchen aselectivereductionofosteosarcomabymitochondrialapoptosisusinghydroxyapatitenanoparticles
AT lixiangfeng aselectivereductionofosteosarcomabymitochondrialapoptosisusinghydroxyapatitenanoparticles
AT zengqin aselectivereductionofosteosarcomabymitochondrialapoptosisusinghydroxyapatitenanoparticles
AT zhouyong aselectivereductionofosteosarcomabymitochondrialapoptosisusinghydroxyapatitenanoparticles
AT yangxiao aselectivereductionofosteosarcomabymitochondrialapoptosisusinghydroxyapatitenanoparticles
AT zhuxiangdong aselectivereductionofosteosarcomabymitochondrialapoptosisusinghydroxyapatitenanoparticles
AT tuchongqi aselectivereductionofosteosarcomabymitochondrialapoptosisusinghydroxyapatitenanoparticles
AT zhangxingdong aselectivereductionofosteosarcomabymitochondrialapoptosisusinghydroxyapatitenanoparticles
AT wuhongfeng selectivereductionofosteosarcomabymitochondrialapoptosisusinghydroxyapatitenanoparticles
AT liushuo selectivereductionofosteosarcomabymitochondrialapoptosisusinghydroxyapatitenanoparticles
AT chensiyu selectivereductionofosteosarcomabymitochondrialapoptosisusinghydroxyapatitenanoparticles
AT huayuchen selectivereductionofosteosarcomabymitochondrialapoptosisusinghydroxyapatitenanoparticles
AT lixiangfeng selectivereductionofosteosarcomabymitochondrialapoptosisusinghydroxyapatitenanoparticles
AT zengqin selectivereductionofosteosarcomabymitochondrialapoptosisusinghydroxyapatitenanoparticles
AT zhouyong selectivereductionofosteosarcomabymitochondrialapoptosisusinghydroxyapatitenanoparticles
AT yangxiao selectivereductionofosteosarcomabymitochondrialapoptosisusinghydroxyapatitenanoparticles
AT zhuxiangdong selectivereductionofosteosarcomabymitochondrialapoptosisusinghydroxyapatitenanoparticles
AT tuchongqi selectivereductionofosteosarcomabymitochondrialapoptosisusinghydroxyapatitenanoparticles
AT zhangxingdong selectivereductionofosteosarcomabymitochondrialapoptosisusinghydroxyapatitenanoparticles